Previous 10 | Next 10 |
2023-12-15 10:00:27 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Myomo, Aileron...
2023-12-15 06:07:59 ET Related stock stories Scholastic Corporation (SCHL) Q2 2024 Earnings Call Transcript Scholastic Corporation 2024 Q2 - Results - Earnings Call Presentation Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript For further details...
2023-12-14 17:20:02 ET More on Aadi Bioscience Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript Aadi Bioscience Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Aadi Bioscience Historical earnings data for Aadi Bioscience F...
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations PR Newswire Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 ...
2023-11-08 12:26:02 ET Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President, Investor Relations and Corporate Communications Scott Giacobello - CFO Dave Lennon - Presid...
2023-11-08 08:05:41 ET More on Aadi Bioscience Aadi Bioscience Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Aadi Bioscience Historical earnings data for Aadi Bioscience Financial information for Aadi Bioscience For further details s...
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update PR Newswire PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of early interim analysis by mid-Decembe...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Aadi Bioscience Inc. (AADI) is expected to report $-0.73 for Q3 2023
2023-11-07 15:14:43 ET More on Aadi Bioscience Seeking Alpha’s Quant Rating on Aadi Bioscience Historical earnings data for Aadi Bioscience Financial information for Aadi Bioscience For further details see: Aadi Bioscience Q3 2023 Earnings Preview
News, Short Squeeze, Breakout and More Instantly...
Aadi Bioscience to Participate in the Jefferies Healthcare Conference PR Newswire LOS ANGELES , May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapi...
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhi...